This is a multicenter, retrospective cohort study that aims to evaluate the efficacy and safety of a triple-drug cocktail (TCC), consisting of Thalidomide, Carmofur, and Compound Mylabris Capsules (CMC), in combination with conventional Transarterial Chemoembolization (TACE) for the treatment of patients with unresectable Hepatocellular Carcinoma (HCC).
Study Type
OBSERVATIONAL
Enrollment
545
Thalidomide tablets (Changzhou Pharmaceutical Factory, 50 mg qn)
carmofur tablets (Qilu Pharmaceutical, 100 mg, tid)
CMC (Guizhou Yibai Pharmaceutical Co., Ltd, 750 mg, bid)
Zhongshan Hospital, Fudan University
Shanghai, China
Overall Survival (OS)
Defined as the time interval from the date of the patient's first TACE treatment to the date of death from any cause or the date of the last follow-up (whichever occurred first).
Time frame: up to five years
Objective Response Rate (ORR) at 6 Months
The proportion of patients achieving a Complete Response (CR) or Partial Response (PR) according to mRECIST criteria at the 6-month follow-up after treatment initiation.
Time frame: up to six months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
received initial treatment with traditional TACE by well-trained and experienced physicians